PDS Financial Statements From 2010 to 2025

PDSB Stock  USD 1.20  0.04  3.23%   
PDS Biotechnology's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing PDS Biotechnology's valuation are provided below:
Market Capitalization
56.7 M
Earnings Share
(0.91)
We have found one hundred twenty available trending fundamental ratios for PDS Biotechnology Corp, which can be analyzed and compared to other ratios and to its competitors. All investors should make sure to check out all of PDS Biotechnology Corp recent market performance against the performance between 2010 and 2025 to make sure the company can sustain itself next year.
Check PDS Biotechnology financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among PDS Biotechnology's main balance sheet or income statement drivers, such as Depreciation And Amortization of 95.7 K, Interest Expense of 4.9 M or Research Development of 16.9 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 3.28. PDS financial statements analysis is a perfect complement when working with PDS Biotechnology Valuation or Volatility modules.
  
Build AI portfolio with PDS Stock
Check out the analysis of PDS Biotechnology Correlation against competitors.

PDS Biotechnology Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets58.7 M45.4 M47.1 M
Slightly volatile
Short and Long Term Debt Total11.4 M21.8 M8.1 M
Slightly volatile
Other Current Liabilities3.6 M2.8 M3.3 M
Pretty Stable
Total Current Liabilities17.9 M17.1 M7.4 M
Slightly volatile
Property Plant And Equipment Net289 K304.2 K876.9 K
Very volatile
Cash55.8 M41.7 M44.7 M
Slightly volatile
Non Current Assets Total289 K304.2 K922.8 K
Pretty Stable
Cash And Short Term Investments55.8 M41.7 M44.7 M
Slightly volatile
Common Stock Shares Outstanding38.3 M36.5 M12.1 M
Slightly volatile
Liabilities And Stockholders Equity58.7 M45.4 M47.1 M
Slightly volatile
Non Current Liabilities Total9.4 M9.3 M10.2 M
Very volatile
Other Current Assets3.5 M3.4 M1.4 M
Slightly volatile
Other Stockholder Equity132.7 M201.1 M106.4 M
Slightly volatile
Total Liabilities20.8 M26.4 M17.1 M
Slightly volatile
Total Current Assets57.5 M45.1 M46.1 M
Slightly volatile
Common StockK12.5 K6.5 K
Slightly volatile
Accounts Payable2.5 M1.7 M2.1 M
Slightly volatile
Net Receivables3.3 K3.5 K119.4 K
Slightly volatile
Common Stock Total Equity7.5 K11.4 K6.4 K
Slightly volatile
Property Plant And Equipment Gross435.2 K458.1 K928.8 K
Very volatile
Other Assets1.091.1591.8 K
Very volatile
Long Term Debt13.7 M9.2 M11.6 M
Slightly volatile
Long Term Debt Total16.1 M26.5 M14.4 M
Slightly volatile
Capital Surpluse122.2 M131 M158.6 M
Slightly volatile
Property Plant Equipment438.1 K474.8 K1.2 M
Slightly volatile
Intangible Assets37.4 K37.5 K46 K
Slightly volatile
Net Invested Capital51.2 M40.7 M62.7 M
Slightly volatile
Net Working Capital34.7 M28 M57.2 M
Slightly volatile
Other Liabilities233 K262.1 K285.8 K
Slightly volatile
Capital Stock9.8 K12.5 K9.8 K
Pretty Stable
Capital Lease Obligations116.8 K123 K504.6 K
Slightly volatile

PDS Biotechnology Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization95.7 K59.8 K76.9 K
Slightly volatile
Interest Expense4.9 M4.7 M1.3 M
Slightly volatile
Research Development16.9 M22.6 M14 M
Slightly volatile
Cost Of Revenue109.5 K59.8 K82.2 K
Slightly volatile
Total Operating Expenses27 M36.3 M22.2 M
Slightly volatile
Selling General Administrative12 M13.5 M9.3 M
Slightly volatile
Interest Income2.6 M2.5 M997.2 K
Slightly volatile
Reconciled Depreciation20.1 K21.1 K113.2 K
Slightly volatile
Extraordinary Items10.9 M12.2 M13.3 M
Slightly volatile
Non Operating Income Net Other44 K49.5 K54 K
Slightly volatile
Selling And Marketing Expenses211.2 K237.6 K259.1 K
Slightly volatile

PDS Biotechnology Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation37 K21.1 K40.2 K
Very volatile
Capital Expenditures27.6 K29 K203.8 K
Pretty Stable
End Period Cash Flow55.8 M41.7 M44.7 M
Slightly volatile
Stock Based Compensation4.7 M6.8 M3.5 M
Slightly volatile
Begin Period Cash Flow53.5 M56.6 M39.8 M
Slightly volatile
Cash And Cash Equivalents Changes10.1 M7.7 M14.2 M
Slightly volatile
Cash Flows Other Operating2.5 M4.3 M1.7 M
Slightly volatile
Dividends Paid217244266
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Average Payables2.1 M3.7 M2.4 M
Pretty Stable
Capex To Depreciation1.31.37365.9495
Slightly volatile
Payables Turnover0.05940.03550.0566
Slightly volatile
Cash Per Share1.091.143729.6671
Very volatile
Days Payables Outstanding9.1 K10.3 K13.3 K
Pretty Stable
Income Quality0.750.93140.8697
Pretty Stable
Intangibles To Total Assets4.0E-45.0E-45.0E-4
Very volatile
Current Ratio2.52.63676.3887
Pretty Stable
Capex Per Share8.0E-48.0E-40.1805
Slightly volatile
Interest Debt Per Share0.690.7272.948
Very volatile
Debt To Assets0.30.48120.3692
Slightly volatile
Days Of Payables Outstanding9.1 K10.3 K13.3 K
Pretty Stable
Ebt Per Ebit1.01.05940.9251
Very volatile
Effective Tax Rate0.02150.02260.1084
Very volatile
Quick Ratio2.52.63676.3887
Pretty Stable
Net Income Per E B T0.930.97741.5375
Very volatile
Cash Ratio2.322.43986.1472
Pretty Stable
Free Cash Flow Operating Cash Flow Ratio1.131.151.03
Slightly volatile
Debt Ratio0.30.48120.3692
Slightly volatile

PDS Biotechnology Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap56.2 M53.5 M26 M
Slightly volatile

PDS Fundamental Market Drivers

Cash And Short Term Investments41.7 M

PDS Upcoming Events

26th of March 2024
Upcoming Quarterly Report
View
20th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
26th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About PDS Biotechnology Financial Statements

PDS Biotechnology stakeholders use historical fundamental indicators, such as PDS Biotechnology's revenue or net income, to determine how well the company is positioned to perform in the future. Although PDS Biotechnology investors may analyze each financial statement separately, they are all interrelated. For example, changes in PDS Biotechnology's assets and liabilities are reflected in the revenues and expenses on PDS Biotechnology's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in PDS Biotechnology Corp. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue28.8 K30.2 K
Cost Of Revenue59.8 K109.5 K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether PDS Biotechnology Corp offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of PDS Biotechnology's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Pds Biotechnology Corp Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Pds Biotechnology Corp Stock:
Check out the analysis of PDS Biotechnology Correlation against competitors.
You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of PDS Biotechnology. If investors know PDS will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about PDS Biotechnology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.91)
Return On Assets
(0.38)
Return On Equity
(1.19)
The market value of PDS Biotechnology Corp is measured differently than its book value, which is the value of PDS that is recorded on the company's balance sheet. Investors also form their own opinion of PDS Biotechnology's value that differs from its market value or its book value, called intrinsic value, which is PDS Biotechnology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because PDS Biotechnology's market value can be influenced by many factors that don't directly affect PDS Biotechnology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between PDS Biotechnology's value and its price as these two are different measures arrived at by different means. Investors typically determine if PDS Biotechnology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, PDS Biotechnology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.